Kornimate/medical-research-clean huggingface dataset:
the effectiveness of an eating disorders prevention program for young women in saudi arabia

Conditions: Eating Disorder Symptom and Body Image Dissatisfaction

Summary: the trial is a randomized control trial about the effective of an eating disorders prevention programmer for young saudi women. the prevention program is title the body project. participants will be saudi undergraduates from princess nourah bint abdulrahman university. sample size is 64 participants. they will be divided randomly to two groups, each group has 32 participants. the first group is the intervention group where the prevention program will be provided. the second group will be the control group where healthy eating education material will be provided. the outcomes will be measured with adapted tools to local culture at three points (pre, post and 3 month follow-up).


Eligibility criteria:
inclusion criteria: undergraduate saudi female exclusion criteria: undergraduate saudi female with eating disorders
covid-19 and the developement of phobic fears of disease

Conditions: COVID19

Summary: a lot of people suffer from phobias. phobias concerning certain diseases are not rare. this study will examine whether the covid-19 (coronavirus disease) crisis was able to rise phobias in people and if those with preexisting phobias or fears were more likely to develop a phobia concerning covid. it will look at different subtypes - physicians, medical staff, general public (not medically affiliated) and patients with psychiatric disorders.


Eligibility criteria:
inclusion criteria: * person gives written consent * persons between 18-90 years of age (men and women) * no positive covid infection known at time of first examination exclusion criteria: * dementia, delirium (not able to give consent) * not fulfilling the inclusion criteria * covid infection known at first examination point
blood pressure tracking--childhood to young adulthood

Conditions: Cardiovascular Diseases; Heart Diseases; Hypertension

Summary: to extend analyses of blood pressure (bp) tracking to a period that spanned childhood and young adulthood. data were used from the same cohort of 339 children who had been followed for nine to twelve years in a previous study.

background: blood pressure measurements in childhood and young adulthood are less predictive of future levels than those taken in middle age. in part, this may be due to the fact that within-person variability appears to make up a larger proportion of total variability in childhood than adulthood. previous work on an nhlbi supported grant indicated that repeated blood pressure measurements and visits led to higher childhood tracking correlations over a period of three years. design narrative: follow-up data were used as well as multiple visits which reduced the large within-person variability of blood pressure measurements and improved the tracking correlations. in addition, 'true' or 'corrected' tracking correlations were provided by eliminating the effects of random measurement error. the effects were examined of time-varying covariates on both the observed and true tracking correlations. besides computing tracking correlations, predictive values were computed for young adult blood pressure given childhood levels. this was the probability that a young adult's true blood pressure was above a specific cutpoint conditional on childhood blood pressure. these values were validated using data from the fels longitudinal study, which included serial blood pressure measurements over the age range in the study. the prediction models were also derived including terms for covariates such as age, sex, height and weight. from these models nomograms were constructed which were useful to physicians for prognostic purposes. thus, because of the unique multiple-visit approach used in these data, the effect of random measurement error was eliminated. these methodologic improvements strengthened the usefulness of blood pressure screening in childhood to detect those at high risk of developing hypertension. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
repetitive transcranial magnetic stimulation in essential tremors patients

Conditions: Essential Tremor

Summary: the aim of the study is to investigate the effect of repetitive transcranial magnetic stimulation on essential tremors.

prior to start of rtms sessions, clinical evaluation and scaling of tremors using the et rating scale (fahn, tolosa, marin tremor rating scale) will be employed on the participants in both groups. rtms frequency of 1hz will be delivered to each of the participants in both groups. each session will be administered once daily for 3 days a week for 4 weeks. 1200 pulses (30 pulses per train with total 40 trains having inter-train delay of 3 seconds) per session will be provided with the coil placed on both cerebellar hemispheres. rtms frequency of 1hz was kept constant based on previous studies. rtms sessions will be administered by trained professionals who was kept blinded to the research protocols used in the study. after completion of therapeutic programs (after 4 weeks), the participants will be asked to undergo post assessment of fahn, tolosa, marin tremor rating scale at the end of last rtms session, 1 month, 3 months later.

Eligibility criteria:
inclusion criteria: 1. patient diagnosed with essential tremors or essential tremors plus based on the movement disorders consensus criteria(appendix 1) 2. patient should have significant residual tremors despite of using appropriate medical treatment. 3. age: patient should be above 18 years old. 4. gender: males and females. exclusion criteria: 1. patients with history of seizures. 2. patient receiving tremor active drugs including: * central cholinergic drugs (acetylcholine chloride, muscarinic and nicotinic agonists, anticholinesterases, and aminopropranolols) * central monoaminergic drugs (neuroleptics, phenylethylamines, and indoles) * peripheral adrenergic drugs (lithium carbonate, amphetamine sulfate, adrenocorticosteroids, and thyroid hormone supplements) * anticonvulsants (valproic acid), bronchodilators (theophylline and terbutaline sulfate) * antidepressants (amitriptyline hydrochloride). 3. patients who have metal or electronic device implanted in their body such as : * cardiac peace maker * aneurysm clips or coils * stents in the neck or brain * deep brain stimulators * spinal cord stimulators * electrodes to monitor brain activity * metallic implants in ears and eyes * bullet fragments in or near the head * baclofen pumps * other metal devices or object implanted in or near the head

Keywords: rtms, essential tremors
integrated supported biopsychosocial self-management for back related leg pain

Conditions: Low Back Pain; Sciatica; Back Related Leg Pain; Pain, Chronic; Intervertebral Disc Displacement

Summary: guidelines advocate several complementary modalities as alternatives to drugs and other invasive treatments for chronic low back pain (lbp) conditions. however, there is little high-quality research investigating treatments for back-related leg pain, one of the more severe and disabling presentations of lbp. the investigators are conducting a pilot study to assess the feasibility of a future phase ii multi-site randomized clinical trial (rct). the future trial will assess the comparative effectiveness of a novel supported biopsychosocial self-management (sbsm) intervention versus medical care (mc).


Eligibility criteria:
inclusion criteria: * back-related leg pain (brlp) consistent with the quebec task force (qtf) classifications 2-4 (radiating pain into proximal or distal extremity with or without neurological signs). * 18 years of age or older. * back-related leg pain severity of 3 or higher at all screening assessments (0 to 10 scale) * episode duration of 12 weeks or more * ability to read english fluently exclusion criteria: * spinal stenosis (qtf 7) * specific, non-mechanical causes of brlp (qtf 11; e.g. infection, tumor) * contraindications to study interventions (e.g. spinal fracture (qtf 5)) * inflammatory conditions of the lumbar spine (qtf 11) * lumbar fusion * progressive neurological deficits * cauda equina syndrome * pregnancy, nursing * ongoing care from another healthcare provider for brlp * severe unmanaged comorbid conditions (e.g. substance abuse, major depressive disorder, stage 3 hypertension).
a phase ib pharmacodynamic study of neoadjuvant paricalcitol in resectable pancreatic cancer a phase ib pharmacodynamic study of neoadjuvant paricalcitol in resectable pancreatic cancer

Conditions: Pancreatic Cancer

Summary: the main purpose of this study is to look at the potential effects of paricalcitol (a drug similar to vitamin d) on pancreatic tumors in patients who are planned for surgical removal of their tumor. the study will also look at the safety of paricalcitol prior to surgery.


Eligibility criteria:
inclusion criteria: * previously untreated, apparently resectable, adenocarcinoma of the pancreas at registration. * age greater than or equal to 18 years * medically fit for surgery in the opinion of the treating surgeon * ability to provide written informed consent exclusion criteria: - patients who are currently pregnant, planning to become pregnant, or breast-feeding. note: women of childbearing potential must agree to use a medically accepted form of birth control including (condoms, diaphragms, cervical cap, an intra-uterine device (iud), surgical sterility \[tubal ligation or a partner that has undergone a vasectomy\], or oral contraceptives). or must agree to completely abstain from intercourse for two weeks before beginning study treatment, during participation in this study, and for 2 weeks after the final study treatment * patients with hypercalcemia (blood levels greater than 11.5 mg/dl). note: in patients with gfr 30-60 ml/min by cockroft-gault, blood calcium levels must be 9.5 mg/dl or lower before starting paricalcitol. * serum creatinine \> 2.5 x uln or gfr \<30 ml/min by cockroft-gault formula . patients who, in the opinion of the physician, would not be clinically appropriate for receipt of the therapy regimen associated with participation.
music therapy/physical therapy intervention to enhance well-being and functional recovery post-stroke

Conditions: Stroke With Hemiparesis

Summary: the purpose of this study is to see if group music therapy and physical therapy will help in the recovery from stroke. it is hoped that music and physical therapy in a group setting will help physical, mental, and social well-being.

the purpose of the study is to investigate the feasibility and efficacy of an "enriched," combined music therapy/physical therapy (mt/pt) rehabilitation intervention that addresses physical, psychological, and social well-being simultaneously in a group setting to enhance post-stroke recovery. the intervention will be implemented through collaboration between the nordoff-robbins center for music therapy at nyu steinhardt and the motor recovery laboratory at the rusk institute of rehabilitation medicine, nyu medical center.

Eligibility criteria:
inclusion criteria: 1. able to read and write in english 2. unilateral stroke at least 6 months prior 3. independent community ambulation with or without assistive devices 4. presence of at least 5 degrees of active motion in proximal and distal upper extremity joints, suggesting presence of a neural substrate for recovery exclusion criteria: 1. neurological or psychiatric disease such as clinical depression 2. hearing deficits 3. history of surgery or other significant injury that could preclude task performance 4. complicating medical problems such as uncontrolled hypertension, diabetes with signs of neuropathy, and previous neurological illness such as head trauma, prior stroke, epilepsy or demyelinating disease 5. any factors that may put the subject at significant risk or confound study results

Keywords: rehabilitation fingers grasp strength brain function physiopathology functional laterality psychomotor performance biomechanis touch music therapy weight-bearing
medications development for drug abuse disorders

Conditions: Opioid Related Disorders; Opioid Dependence; Opioid Addiction

Summary: this is a study of tramadol as an agent for short-term opioid withdrawal treatment. a randomized, double blind clinical trial comparing the efficacy and safety of tramadol to clonidine and buprenorphine in the short-term treatment of opioid withdrawal will be conducted. opioid dependent participants will be treated on a residential unit. the primary outcome measure is opioid withdrawal symptoms.


Eligibility criteria:
inclusion/exclusion criteria: * participants in this study will be males and females between the ages of 18 and 60 years. * applicants must be opioid dependent based upon the structured clinical interview for diagnostic and statistical manual of mental disorders (dsm-iv) (scid); in addition, they must have an opioid positive urine during the screening process (or have evidence of opioid withdrawal). * they must be healthy, with no significant medical illnesses (e.g., insulin dependent diabetes), and without significant psychiatric illness (e.g., schizophrenia) besides their drug dependence. * females will have a pregnancy test prior to study enrollment, and if found to be pregnant will be excluded and referred to a substance abuse program for pregnant women (the center for addiction and pregnancy) on the campus. * volunteers will also be excluded if they have pre-admission hypotension (due to the use of clonidine in the study). * applicants with a history of seizures (including substance-related seizures, such as alcohol withdrawal related) will be excluded. * alcohol and/or sedative dependence will be specific exclusionary criteria (given the small risk of seizures associated with tramadol use). * allergies to any of the study medications will be grounds for exclusion.
efficacy & safety of 980nm diode laser vs. cryotherapy for plantar warts

Conditions: Warts of Foot

Summary: the goal of this clinical trial is to compare and test the efficacy of two treatments for plantar warts. the main questions it aims to answer are: which treatment has a higher cure rate for eliminating plantar warts? which treatment causes less pain during the procedure? participants with plantar warts will: be randomly assigned to receive either cryotherapy or laser therapy undergo 4 treatment sessions at weekly intervals have their warts assessed for complete clearance after treatment rate their pain levels during each session researchers will compare the cryotherapy and laser therapy groups to see if there are differences in: rates of complete wart clearance pain levels reported during treatment adverse effects

background: plantar warts are a common dermatological condition caused by human papillomavirus infection. they can be painful and negatively impact quality of life. many treatments exist but there is lack of consensus on the optimal approach. objectives: primary objective: to compare the efficacy of 980nm diode laser versus liquid nitrogen cryotherapy for clearing plantar warts, as measured by the complete clearance rate at 4 weeks post-treatment. secondary objectives: to evaluate and compare pain levels during treatment procedures and adverse events between both groups. study design: randomized, double-blind clinical trial. participants: 32 patients aged 18-65 years old with 1-3 plantar warts located on weight-bearing areas of the foot. interventions: laser group: 980nm diode laser applied to each wart for 5 seconds at 2w power and 1mm spot size. 4 sessions at weekly intervals. cryotherapy group: liquid nitrogen sprayed on each wart using a standardised technique. freeze-thaw cycle repeated up to 3 times per wart per session. 4 sessions at weekly intervals. main outcomes: complete clearance rate of plantar warts at 4 weeks treatment session. assessed by physical examination. pain during procedure measured with visual analogue scale (vas). adverse events monitored during follow-up. randomization and blinding: subjects will be randomly allocated to each group with a 1:1 ratio. investigators assessing outcomes will be blinded to group assignment. analysis: intention-to-treat analysis will be performed. chi-squared test will compare clearance rates. t-test will compare pain scores.

Eligibility criteria:
inclusion criteria: * patients with recalcitrant, mosaic and simple hpv exclusion criteria: * diabetic, ischaemic and immunosuppressed patients * patients with cold intolerance * patients with any of the following conditions (blood dyscrasias of unknown origin, cryoglobulinaemia, cryofibrinogenemia, collagen or autoimmune disease) * patients who do not sign the informed consent form.

Keywords: cryotherapy laser therapy papillomaviridae plantar warts randomised clinical trial
a pilot study of bone mineral density in postmenopausal women after treatment for breast cancer

Conditions: Postmenopausal Bone Loss; Breast Cancer

Summary: the main purpose of this study is to see what levels of bone mineral density post-menopausal women with breast cancer have, and to see if the level of bone mineral density changes during a women's treatment after her surgery. this trial studies changes in bone mineral density and markers of of bone activity in post-menopausal women receiving treatment for early stage breast cancer.


Eligibility criteria:
inclusion criteria: * documented diagnosis of breast cancer * last menstrual period occurring more than 5 years ago * non-metastatic breast cancer tumor with the diagnosis of tis, tl-t4, n0-3, m0 * dcis is allowed, but lcis (only) is not exclusion criteria: * any metabolic bone disease other than postmenopausal osteoporosis or osteopenia * use of systemic gonadal hormonal medications or supplements within the past 24 months * prior use of tamoxifen or raloxifene is permitted if the medication was discontinued more than 24 months prior to the diagnosis of breast cancer. * no adjuvant antiestrogen, antineoplastic, therapies are permitted on study. * chronic use of systemic steroids for disease process other than breast cancer chemotherapy premedication or antiemetics * history of rheumatoid arthritis, ankylosing spondylitis, hyperparathyroidism, renal osteodystrophy, moderate to severe inflammatory or autoimmune disease or newly diagnosed thyroid condition requiring titration of medications. * lobular carcinoma in situ or stage iv breast cancer and patients with a concurrently active second malignancy other then adequately treated non-melanoma skin cancers or in situ cervical cancer. * participation in other clinical trials that are measuring bmd as a study parameter * patients with conditions that are expected to distort bmd reading and make dexa results unreliable * patients with concurrent medical or psychiatric conditions that would keep them from understanding and complying with this clinical trial.

Keywords: post menopause women receiving adjuvant care
reduction of demoralization in patients with tardive dyskinesia after treatment with valbenazine

Conditions: Tardive Dyskinesia

Summary: this will be an investigator-initiated pilot study in which participants will be assessed with various scales to measure demoralization, anxiety, depression, and subjective incompetence at baseline and every two weeks after treatment with valbenazine for a total of 6 weeks. improvement in td will be assessed as well and correlated with reduction in demoralization.


Eligibility criteria:
inclusion criteria: 1. age: 26-84 2. sex: both males and females will be included 3. diagnosis of dopamine receptor-blocker induced tardive dyskinesia according to the dsm-5 criteria: "involuntary athetoid or choreiform movements lasting at least a few weeks, developing in association with the use of a neuroleptic medication for at least a few months, and persisting beyond 4-8 weeks" exclusion criteria: the following classes of patients will be excluded: 1. patients with unstable psychiatric status defined as having a total score on bprs of 50 or higher 2. patients who have suicidal or homicidal ideation, intent, or plan or viewed as having a significant risk of suicidal or violent behavior; 3. patients with cognitive impairment as defined by a score of 24 or less on the mmse 4. patients with current diagnosis of alcohol or substance use disorder made according to dsm-5 criteria 5. patients with clinically significant unstable medical condition defined as follows: a comorbid abnormal movement disorder more prominent than tardive dyskinesia (e.g., parkinsonism, akathisia, truncal dystonia), a score of greater than 2 on two or more items of the simpson-angus scale, or a history of neuroleptic malignant syndrome. 6. patients previously treated with valbenazine or any other medication specifically indicated for tardive dyskinesia 7. patients currently taking strong cyp3a4 inducers, dopamine agonists, mao inhibitors, stimulants, and/or vmat2 inhibitors 8. patients with congenital long qt syndrome or arrhythmias associated with prolonged qt interval 9. patients with risk factors for prolonged qt such as electrolyte abnormalities (hypokalemia, hypocalcemia, hypomagnesemia), anorexia nervosa, diuretic use, certain heart conditions, and other medical conditions 10. patients tested positive for coronavirus covid-19 11. patients with impaired decision-making capacity 12. institutionalized individuals 13. prisoners
study of cm310 in patients with allergic rhinitis

Conditions: Allergic Rhinitis

Summary: this study is a multicenter, single arm, open-label phase ii clinical study mainly evaluating the safety of cm310 in patients with allergic rhinitis.

allergic rhinitis (ar) is a non infectious chronic inflammatory disease of the nasal mucosa that is mainly mediated by immunoglobulin e (ige) in atopic individuals exposed to allergens.

Eligibility criteria:
inclusion criteria: * male or female aged 18-65. * understand the study and sign the informed consent form voluntarily. * take effective contraception measures throughout the study period. exclusion criteria: * used other investigational drugs. * allergies to drugs with il-4rα monoclonal antibody or drug components of cm310. * plan to participate in other studies during this clinical trial. * with malignant or benign tumors of the nasal cavity. * other reasons the researcher believes that the subject is not suitable to participate in this study.
effectiveness of hexaminolevulinate (hexvix) in the diagnosis and treatment of patients with non-invasive bladder cancer

Conditions: Bladder Cancer

Summary: the purpose of this study is to determine the effectiveness of hexaminolevulinate (hexvix) in the diagnosis and treatment of patients with non-invasive bladder cancer and if it results in a change in patient management.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age. * patients of either sex. * patients with documented or highly suspected non-invasive bladder cancer. exclusion criteria: * patients with hypersensitivity to the drug substance or any excipient of hexvix. * patients with porphyry. * women of childbearing age. * patients at a high risk of suffering extensive bladder inflammation e.g. patients after intravesical bcg treatment, patients with moderate or severe leukocyturia or patients undergoing recent bladder surgery.

Keywords: bladder cancer cystoscopy hexaminolevulinate hexvix